Clinical trial
CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma
NCT06913179 is registered in ClinicalTrials.gov with Xuzhou Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Multiple Myeloma
- Lead sponsor
- Xuzhou Medical University
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- April 1, 2025
- Completion date
- March 31, 2028
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.